Conventional wisdom that U.S. pharmaceutical companies made out well under the Obama health plan by bargaining with the White House is wrong.

Panelists discuss competitive pricing in Medicare.

The $2 billion loss by JPMorgan Chase has reawakened debate about whether banks are taking excessive risks, but many facts have gotten lost in the breathless media coverage.

Does Congress need IPAB?

Even comparative effectiveness proposals will hamper new drug development.

Indeed, price controls are one of the most pernicious kinds of government regulation. In an ironic twist, they often lead to higher consumer prices over time because they build inefficiencies into economic transactions and decision-making that end up costing consumers more money in the long run.

The U.S. trade representative should be exerting pressure immediately in bilateral talks with countries like Germany to end counterproductive price controls, as the world's health is at stake.